Adom Dumanian, Mesh Suture - Wound Closure Device | LSI USA '24

Adom Dumanian  0:03  
My name is Adom and I'm the CEO of Mesh Suture Inc, a global commercial stage company based in Chicago. The company was founded by Dr. Dumanian, who's the Chief of Plastic Surgery at Northwestern in Chicago. He's a world renowned academic surgeon and abdominal wall reconstruction. And throughout the years, it always bothered Dr. Dumanian that sutures could cut his fingers even while he was wearing three gloves in the operating room. And he was thinking if this is what it's doing in my fingers, how are sutures treating my patients? And surgeries best kept secret is that when you cut into the abdomen for anything, transplant, plastic surgery, general surgery, gunshot wound anything, there's a 22% chance that the patient will get a hernia at that incision. The Cleveland Clinic actually just came out with data last year that if you have a BMI over 30, that percentage is as high as 50. And that is because sutures are cutting the very tissues that they're supposed to be holding together. And because of the lack of innovation in the suture itself, incredibly high failure rates are tolerated across all of surgery, almost 40% of rotator cuffs fail, and percent of umbilical hernias that are sutured fail. And it's evident that suture that surgeons lack and effective closure device to securely close the soft tissue defects. And this is where we come in. During mesh is a Mesh Suture it flattens like a ribbon to distribute tension across the suture tissue interface and then allows your tissue to grow into the core of the suture itself for a long term durable repair. So is it working? Well, we have been on the market since January 23. And a registry study just came out a few months ago, included 379 cases 56 different surgeons used it in one hospital system and the first six months and during mesh had superior outcomes to standard suture and comparable series, no literature, mainly lower SSC and SSI and lower dehiscence rates. So why is it working? Well, first, it's strong from the start. Like I said, it flattens like a ribbon to distribute the tension and the pressure at the suture tissue interface. I mean, just look at that standard suture. No wonder it cuts through tissue. This is the most important picture I'm going to show today. And this is from pig histology at three months. You can see the suture flattening towards the laparotomy closure, but more importantly, you can see healthy tissue incorporation and each filament being encapsulated by the tissues showing incredibly healthy tissue incorporation. This is written up in the British Journal of surgery. This is a pig laparotomy at eight days with Mesh Suture versus standard suture and the mesh future repairs were twice as strong and took triple the amount of work to fail as standard suture repairs. And lastly, it allows for a simple surgical technique. The surgeon can maintain his or her known materials handling not time, so they're very limited adoption barriers to entry. This is a hiatal hernia repair this procedure actually has a 50% failure rate at five years and you can see it handles nicely robotically. You can see it flatten the pores are open tournament tissue incorporation and then not slide down just like standard sutures again, limited adoption barriers tech tree. Durham F mesh is available in seven different sizes ranging from two Oh USB to number two. It comes with a small needle that can fit through an eight millimeter port again can use robotically or laparoscopically or as large needle for open procedures. It can be used in a whole host of different use cases. You know tendon repair hiatal hernias, Ventspils laparotomy closure, breast reconstruction, you name it. In the early feedback has been quite positive. Europeans are saying they love it. Other surgeons are saying that they're sold and that we're on to something. So our company has been around since 2012. We received funding in 2018 and 2019, raising a total of $10.4 million. He received our CE mark under MDD and 2021 and launched in the EU, after securing some distribution partners in 2020 to be received our FDA clearance late 2022 and launched in the US in January 2023 and anticipate receiving our MDR clearance later this calendar year. We have 45 issued patents in 29 countries in addition to multiple trade secrets in manufacturing. And we believe these are both strong barriers to entry for any other vendors who want to manufacture or sell that features. Even at half capacity, our current production can support upwards of $75 million in revenue, and our three PL warehousing order fulfillment. It just is a distributor for a pretty well known 100 billion dollar plus orthopedic company, so we don't anticipate any issues for scaling on that front. Our team I mentioned Dr. DE Manya. And we have Renda, who's a former NASA rocket scientist and has 10 years of med device experience. They also have Courtney Goodwin, he used to manage Medtronic $200 million plus hernia mesh portfolio advising us on all things commercialization. We have a pretty experienced QA and engineering team along with a couple internal sales reps. And we have a ton of advisors for all things compliance future m&a, and legal. And lastly, just to give you some numbers behind the opportunity about Durham measurement suture, and because Durham mesh can stand to replace both sutures and meshes in a whole host of different surgical specialties, even at a 3% market share journal mesh could generate upwards of 135 million in revenue. Thank you for your time and if you're interested in contacting me or website is mesh future.com And I'll be out back as well. Thank you